<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662311</url>
  </required_header>
  <id_info>
    <org_study_id>6600</org_study_id>
    <secondary_id>NCI-2010-00715</secondary_id>
    <nct_id>NCT00662311</nct_id>
  </id_info>
  <brief_title>Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined With Paclitaxel and Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of vorinostat when given&#xD;
      together with paclitaxel and radiation therapy and to see how well it works in treating&#xD;
      patients unable to tolerate cisplatin with stage III non-small cell lung cancer (NSCLC) that&#xD;
      cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some&#xD;
      of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Giving vorinostat together with paclitaxel and radiation therapy may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of vorinostat when administered in&#xD;
      combination with paclitaxel and thoracic radiation therapy in patients with locally advanced&#xD;
      NSCLC.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and toxicity of vorinostat when administered in combination with&#xD;
      paclitaxel and thoracic radiation therapy in patients with locally advanced NSCLC.&#xD;
&#xD;
      II. To determine the radiological response rate, by computed tomography (CT) scan, of&#xD;
      vorinostat when administered in combination with paclitaxel and thoracic radiation therapy in&#xD;
      patients with locally advanced NSCLC.&#xD;
&#xD;
      III. To describe the progression free survival (PFS) and overall survival (OS) of this&#xD;
      regiment over 3 years of follow up.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of vorinostat followed by a phase II study.&#xD;
&#xD;
      Patients receive vorinostat orally (PO) once daily (QD), 5 days a week and paclitaxel&#xD;
      intravenously (IV) over 1 hour once a week. Patients also undergo radiation therapy QD, 5&#xD;
      days a week. Treatment repeats every week for 7 courses in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, 12 weeks, every 3&#xD;
      months for 2 years, and then every 6 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of Vorinostat When Administered in Combination With Paclitaxel and Radiotherapy Therapy as Assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Defined as the highest dose level at which no more than 1 of 6 patients experiences dose-limiting toxicity (DLT). Toxicity was graded according to the National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. A DLT was defined as any Grade 3 or higher non-hematologic adverse event with the exception of alopecia, fatigue, or anorexia. Nausea and/or vomiting that persisted &gt; 48 hours despite optimal medical management at grade 3 or higher was considered a DLT. Hematologic dose-limiting toxicity was defined as either: Grade 4 neutropenia lasting for â‰¥ 7 days in duration, Grade &gt; 3 febrile neutropenia with/without infection, Grade 4 thrombocytopenia or Grade 5 hematologic toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological Response Rate as Assessed by CT</measure>
    <time_frame>12 weeks post-treatment, then every 3 months for 2 years, and then every 6 months for a year thereafter</time_frame>
    <description>Count of participants with stable disease or partial response. Patients were evaluated for treatment response per RECIST criteria (version 1.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-Meier estimate. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Kaplan-Meier estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Toxicity of Vorinostat at the MTD as Assessed by NCI CTCAE Version 3.0</measure>
    <time_frame>Weekly during treatment, 30 days post-treatment, and 12 weeks post-treatment</time_frame>
    <description>Count of participants with a grade 3 or higher toxicity. Toxicities were assessed using the NCI CTCAE (v3.0). Grade 3 or higher toxicities were considered worse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat with paclitaxel and radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat with paclitaxel and radiotherapy)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat with paclitaxel and radiotherapy)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (vorinostat with paclitaxel and radiotherapy)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of NSCLC&#xD;
&#xD;
          -  Inoperable Stage IIIA or IIIB (excluding malignant pleural effusion) disease according&#xD;
             to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Sixth edition&#xD;
             (2002)&#xD;
&#xD;
          -  At least one site of measurable disease, as defined by the modified Response&#xD;
             Evaluation Criteria In Solid Tumors (RECIST) criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Inability to tolerate full dose cisplatin as defined by:&#xD;
&#xD;
          -  Creatinine clearance less than 50ml/min&#xD;
&#xD;
          -  Greater than grade 2 sensory hearing loss (as defined by National Cancer Institute&#xD;
             [NCI] Common Terminology Criteria for Adverse Events [CTCAE] criteria v3.0 adverse&#xD;
             event term &quot;Hearing: Patients without baseline audiogram and not enrolled in a&#xD;
             monitoring program&quot;)&#xD;
&#xD;
          -  Performance status &gt;= 2&#xD;
&#xD;
          -  Age &gt;= 75 years&#xD;
&#xD;
          -  Cardiac history, such as myocardial infarction within 6 months, angina, or heart&#xD;
             disease as defined by the New York Heart Association (NYHA) Class III or IV&#xD;
&#xD;
          -  Any other comorbid disease or condition that would increase the risk of toxicity of&#xD;
             cisplatin therapy&#xD;
&#xD;
          -  Female patient is either post menopausal, free from menses for &gt;= 2 years, surgically&#xD;
             sterilized or willing to use 2 adequate barrier methods of contraception to prevent&#xD;
             pregnancy or agrees to abstain from heterosexual activity throughout the study&#xD;
&#xD;
          -  Female patient of childbearing potential has a negative serum pregnancy test&#xD;
             beta-human chorionic gonadotropin (hCG) within 7 days prior to receiving the first&#xD;
             dose of vorinostat&#xD;
&#xD;
          -  Male patient agrees to use an adequate method of contraception for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Prothrombin Time or International Normalized Ratio (INR) =&lt; 1.5x upper limit of normal&#xD;
             (ULN) unless receiving therapeutic anticoagulation&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) =&lt; 1.2 times the ULN unless the patient is receiving&#xD;
             therapeutic anticoagulation&#xD;
&#xD;
          -  Potassium levels: Normal limits&#xD;
&#xD;
          -  Magnesium levels: Normal limits&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;= 20 mL/min&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 X ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamate oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 2.5 X&#xD;
             ULN&#xD;
&#xD;
          -  Alkaline Phosphatase =&lt; 2.5 X ULN&#xD;
&#xD;
          -  Patient, or the patient's legal representative, has voluntarily agreed to participate&#xD;
             by giving written informed consent&#xD;
&#xD;
          -  Patient has a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Patient is available for periodic blood sampling, study related assessments, and&#xD;
             management at the treating institution for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has had chemotherapy, radiotherapy, or biological therapy for NSCLC within&#xD;
             5 years prior to initial dosing with study drug(s)&#xD;
&#xD;
          -  Symptomatic neuropathy (&gt;= grade 2)&#xD;
&#xD;
          -  Patient is currently participating or has participated in a study with an&#xD;
             investigational compound or device within 30 days of initial dosing with study drug(s)&#xD;
&#xD;
          -  Patient had prior treatment with an histone deacetylases (HDAC) inhibitor (e.g.,&#xD;
             romidespsin [Depsipeptide, NSC-630176], entinostat [MS 275], dacinostat [LAQ-824],&#xD;
             belinostat [(PXD-101]), panobinostat [LBH589], mocetinostat [MGCD0103], CRA024781,&#xD;
             etc); patients who have received compounds with HDAC inhibitor-like activity, such as&#xD;
             valproic acid, as anti-tumor therapy should not enroll in this study; patients who&#xD;
             have received such compounds for other indications, e.g., valproic acid for epilepsy,&#xD;
             may enroll after a 30-day washout period&#xD;
&#xD;
          -  Patient has known hypersensitivity to the components of study drug or its analogs or&#xD;
             paclitaxel&#xD;
&#xD;
          -  NYHA Class III or IV congestive heart failure, myocardial infarction within the&#xD;
             previous 6 months, QTc &gt; 0.47 seconds, or uncontrolled arrhythmia&#xD;
&#xD;
          -  Patient is pregnant or breast feeding, or expecting to conceive or father children&#xD;
             within the projected duration of the study&#xD;
&#xD;
          -  Patient with a &quot;currently active&quot; second malignancy, other than non-melanoma skin&#xD;
             cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not&#xD;
             considered to have a &quot;currently active&quot; malignancy if they have completed therapy for&#xD;
             a prior malignancy, are disease free from prior malignancies for &gt; 5 years or are&#xD;
             considered by their physician to be at less than 30% risk of relapse&#xD;
&#xD;
          -  Patient has a history or current evidence of any condition, therapy, or lab&#xD;
             abnormality that might confound the results of the study, interfere with the patient's&#xD;
             participation for the full duration of the study or is not in the best interest of the&#xD;
             patient to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shilpen Patel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <results_first_submitted>March 28, 2017</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Shilpen Patel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vorinostat 200 mg</title>
          <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="P2">
          <title>Vorinostat 300 mg</title>
          <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="P3">
          <title>Vorinostat 400 mg</title>
          <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Respiratory Infection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vorinostat 200 mg</title>
          <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="B2">
          <title>Vorinostat 300 mg</title>
          <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="B3">
          <title>Vorinostat 400 mg</title>
          <description>Cohort 3: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" lower_limit="74" upper_limit="80"/>
                    <measurement group_id="B4" value="77" lower_limit="74" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MTD of Vorinostat When Administered in Combination With Paclitaxel and Radiotherapy Therapy as Assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)</title>
        <description>Defined as the highest dose level at which no more than 1 of 6 patients experiences dose-limiting toxicity (DLT). Toxicity was graded according to the National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. A DLT was defined as any Grade 3 or higher non-hematologic adverse event with the exception of alopecia, fatigue, or anorexia. Nausea and/or vomiting that persisted &gt; 48 hours despite optimal medical management at grade 3 or higher was considered a DLT. Hematologic dose-limiting toxicity was defined as either: Grade 4 neutropenia lasting for â‰¥ 7 days in duration, Grade &gt; 3 febrile neutropenia with/without infection, Grade 4 thrombocytopenia or Grade 5 hematologic toxicity.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat 200 mg</title>
            <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Vorinostat 300 mg</title>
            <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O3">
            <title>Vorinostat 400 mg</title>
            <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>MTD of Vorinostat When Administered in Combination With Paclitaxel and Radiotherapy Therapy as Assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I)</title>
          <description>Defined as the highest dose level at which no more than 1 of 6 patients experiences dose-limiting toxicity (DLT). Toxicity was graded according to the National Institutes of Health Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. A DLT was defined as any Grade 3 or higher non-hematologic adverse event with the exception of alopecia, fatigue, or anorexia. Nausea and/or vomiting that persisted &gt; 48 hours despite optimal medical management at grade 3 or higher was considered a DLT. Hematologic dose-limiting toxicity was defined as either: Grade 4 neutropenia lasting for â‰¥ 7 days in duration, Grade &gt; 3 febrile neutropenia with/without infection, Grade 4 thrombocytopenia or Grade 5 hematologic toxicity.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to adverse events we were unable to increase the vorinostat dosing beyond the first cohort of 200mg. The study was terminated prior to identifying the MTD.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiological Response Rate as Assessed by CT</title>
        <description>Count of participants with stable disease or partial response. Patients were evaluated for treatment response per RECIST criteria (version 1.0).</description>
        <time_frame>12 weeks post-treatment, then every 3 months for 2 years, and then every 6 months for a year thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat 200 mg</title>
            <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Vorinostat 300 mg</title>
            <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O3">
            <title>Vorinostat 400 mg</title>
            <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Response Rate as Assessed by CT</title>
          <description>Count of participants with stable disease or partial response. Patients were evaluated for treatment response per RECIST criteria (version 1.0).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>27 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>39 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat 200 mg</title>
            <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Vorinostat 300 mg</title>
            <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O3">
            <title>Vorinostat 400 mg</title>
            <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Kaplan-Meier estimate. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat 200 mg</title>
            <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Vorinostat 300 mg</title>
            <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O3">
            <title>Vorinostat 400 mg</title>
            <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Kaplan-Meier estimate. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0).</description>
          <units>progression free survival probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.035" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Kaplan-Meier estimate</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat 200 mg</title>
            <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Vorinostat 300 mg</title>
            <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O3">
            <title>Vorinostat 400 mg</title>
            <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Kaplan-Meier estimate</description>
          <units>survival probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="0.29" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Toxicity of Vorinostat at the MTD as Assessed by NCI CTCAE Version 3.0</title>
        <description>Count of participants with a grade 3 or higher toxicity. Toxicities were assessed using the NCI CTCAE (v3.0). Grade 3 or higher toxicities were considered worse.</description>
        <time_frame>Weekly during treatment, 30 days post-treatment, and 12 weeks post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat 200 mg</title>
            <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O2">
            <title>Vorinostat 300 mg</title>
            <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
          <group group_id="O3">
            <title>Vorinostat 400 mg</title>
            <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Toxicity of Vorinostat at the MTD as Assessed by NCI CTCAE Version 3.0</title>
          <description>Count of participants with a grade 3 or higher toxicity. Toxicities were assessed using the NCI CTCAE (v3.0). Grade 3 or higher toxicities were considered worse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vorinostat 200 mg</title>
          <description>Cohort 1: Patients receive 200 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="E2">
          <title>Vorinostat 300 mg</title>
          <description>Cohort 2: Patients receive 300 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
        <group group_id="E3">
          <title>Vorinostat 400 mg</title>
          <description>Cohort 3: Patients receive 400 mg vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.&#xD;
vorinostat: Given PO&#xD;
paclitaxel: Given IV&#xD;
radiation therapy: Undergo radiation therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Community Contacted Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Radiation Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shilpen Patel</name_or_title>
      <organization>Departments of Radiation Oncology and Global Health University of Washington Medical Center</organization>
      <phone>206-598-4100</phone>
      <email>shilpenp@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

